Vyluma Inc. · Bridgewater, New Jersey
Case #I-200-22319-588537
A Vice President, Ophthalmic New Drug Development position at Vyluma Inc. in Bridgewater, New Jersey was filed at $300k per year, offering 32% above the prevailing wage of $228k. The case was denied in 2 days during the FY FY2023 cycle. This position is for continued employment.
| Case Number | I-200-22319-588537 |
| Case Status | Denied |
| Visa Class | H-1B |
| Fiscal Year | FY 2023 |
| Employer | Vyluma Inc. |
| Employer Location | Bridgewater, New Jersey |
| Job Title | Vice President, Ophthalmic New Drug Development |
| SOC Code | 11-912100 – Natural Sciences Managers |
| Worksite | Bridgewater, New Jersey |
| Annual Wage | $300k |
| Prevailing Wage | $228k |
| Wage Premium | +31.8% |
| Positions | 1 (0 new, 0 continued) |
| Job Title | Salary | Status | Date |
|---|---|---|---|
| Vice President, Ophthalmic New Drug Development | $300k | CERTIFIED | Nov 22, 2022 |
This Labor Condition Application (LCA) was filed by Vyluma Inc. for the position of Vice President, Ophthalmic New Drug Development in Bridgewater, New Jersey. The offered annual salary is $300k, compared to the prevailing wage of $228k for this occupation and location. This represents a wage premium of +31.8% above the prevailing wage.
The LCA is the first step in the H-1B visa process. Employers must file an LCA with the Department of Labor certifying that they will pay the foreign worker at least the prevailing wage for the occupation in the area of intended employment. A certified LCA is required before the employer can file an H-1B petition with USCIS.
Case status: Denied. This means the Department of Labor has denied the application, possibly due to wage or documentation issues.
A Labor Condition Application (LCA) is a mandatory document that U.S. employers must file with the U.S. Department of Labor (DOL) before they can petition for a foreign worker under the H-1B, H-1B1, or E-3 visa categories. The LCA process was established under the Immigration and Nationality Act (INA) to protect both foreign and domestic workers by ensuring fair wages and working conditions.
When a U.S. company identifies a foreign national to fill a specialty occupation position, they must first obtain DOL certification through the LCA process before filing the H-1B petition (Form I-129) with U.S. Citizenship and Immigration Services (USCIS). In this case, Vyluma Inc. filed LCA case number I-200-22319-588537 to sponsor a Vice President, Ophthalmic New Drug Development position at their worksite in Bridgewater, New Jersey. By filing this LCA, the employer attests to four key conditions: (1) paying the higher of the actual wage or prevailing wage, (2) providing working conditions that will not adversely affect other similarly employed workers, (3) no strike or lockout at the worksite, and (4) providing notice of the filing to the bargaining representative or posting notice at the worksite.
The DOL establishes four wage levels for each occupation and geographic area, representing the progression from entry-level to fully competent workers:
For this filing, the offered wage of $300k compares to the DOL prevailing wage of $228k for Natural Sciences Managers positions in the Bridgewater, New Jersey area. The positive wage premium of +31.8% indicates the employer is offering above the DOL-determined average for this occupation and location.
The prevailing wage is the average wage paid to similarly employed workers in a specific occupation in the area of intended employment. The DOL determines prevailing wages using data from the Occupational Employment and Wage Statistics (OEWS) survey conducted by the Bureau of Labor Statistics (BLS). Employers must pay H-1B workers the higher of the prevailing wage or the actual wage paid to other employees in similar positions at the company. This requirement is designed to prevent employers from using H-1B workers to undercut domestic wages.
A "Denied" status means the DOL has determined that Vyluma Inc.'s LCA did not meet one or more regulatory requirements. Common reasons for denial include: the offered wage falling below the prevailing wage, errors in the application, failure to properly attest to working conditions, or prior violations by the employer. The employer may correct the identified issues and submit a new LCA.
This LCA was received by the DOL on Nov 15, 2022 and a decision was rendered on Nov 17, 2022, a processing time of approximately 2 business days. The standard DOL processing time for LCA applications is 7 to 10 business days. This application was processed within the standard timeframe.
The offered salary of $300k for this Vice President, Ophthalmic New Drug Development position provides a data point for evaluating compensation trends in H-1B visa sponsorship. When reviewing H-1B salary data, consider that wages vary significantly based on geographic location, employer size, industry sector, and the worker's experience level. This position falls under SOC code 11-912100 (Natural Sciences Managers), which standardizes how the Bureau of Labor Statistics classifies occupations across industries. Metropolitan areas like New York, San Francisco, and Seattle typically command higher salaries due to higher costs of living, while positions in smaller markets may offer lower nominal wages but comparable purchasing power.
The offered annual salary for this Vice President, Ophthalmic New Drug Development position at Vyluma Inc. is $300k. The Department of Labor prevailing wage for this occupation and location is $228k. The offered wage represents a +31.8% premium over the prevailing wage.
This H-1B filing is for a position located in Bridgewater, New Jersey. The employing company, Vyluma Inc., is headquartered in Bridgewater, New Jersey.
This Labor Condition Application is filed under the H-1B visa classification. The H-1B visa is designed for specialty occupation workers who possess at least a bachelor's degree or equivalent in a specific field related to the job.
The employer for this filing is Vyluma Inc., located in Bridgewater, New Jersey. Vyluma Inc. filed this Labor Condition Application (case number I-200-22319-588537) for a Vice President, Ophthalmic New Drug Development position during fiscal year FY 2023. View all Vyluma Inc. H-1B filings.
Denied means the U.S. Department of Labor has rejected this Labor Condition Application. Common reasons for denial include offering a wage below the prevailing wage, incomplete documentation, failure to properly attest to working conditions, or prior violations.